Biopharmaceutical company Sigilon Therapeutics reported on Thursday the election of David E. Moller, MD as its chief scientific officer.
Most recently, Dr Moller has served in Eli Lilly as vice president of Business Development - Emerging Technology and Innovation at Eli Lilly as well as vice president of its Endocrine and Cardiovascular Research and Clinical Investigation .
Previously, Dr Moller was employed as vice president, Metabolic Disorders at Merck (MSD), which included oversight of the team responsible for the discovery of sitaglipitin (Januvia), leading the global discovery efforts in diabetes and obesity.
Earlier in his career, Dr Moller was part of the faculty of Harvard Medical School.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Hyperfine Inc and Athletic Heart collaborate to deliver portable brain imaging for former athletes
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy